Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rubicon Organics Inc. (ROMJ.V)
CAD0.45
+0.01 (+1.12%)
CA TSXV Healthcare Drug Manufacturers - Specialty & Generic
Address
744 West Hastings Street V6C 1A5
Vancouver, BC, CA
Vancouver, BC, CA
CEO
Margaret Ruth Brodie
Website
rubiconorganics.com
IPO
2018-10-10
ISIN CA78112W1005
Also trades on
Other OTC · ROMJF (USD)
Toronto Stock Exchange Ventures · ROMJ.V (CAD)
Description
Rubicon Organics Inc. cultivates, processes, and distributes organic cannabis products for both recreational and medicinal consumers across Canada. The company markets its organic cannabis through its proprietary labels as well as various licensed brands. Founded in 2015, Rubicon Organics Inc. maintains its headquarters in Vancouver, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD0.45
+0.01 (+1.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
57.5K
Beta
0.40
Float Shares
37.80M
Free Float %
56.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.35% | -12.00% | -24.79% | +1.15% | -11.11% | -7.37% | +14.29% | -20.00% | -83.70% | -86.46% | -86.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.45
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.29
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+22.1% ★ Q1'26: +10.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+135.3% ★ Q1'26: -610.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.9% Q1'26: -2.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.0% Q1'26: -53.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.4% Q1'26: -56.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.4% Q1'26: +17.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.43× Q1'26: -0.54× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 400.0K (-100.0%)
|
9.39M
est: 10.35M (-9.3%)
|
22.61M
est: 22.60M (+0.1%)
|
35.52M
est: 34.75M (+2.2%)
|
40.12M
est: 41.03M (-2.2%)
|
48.70M
est: 48.20M (+1.0%)
|
59.45M
est: 58.85M (+1.0%)
|
72.07M
70.84M – 73.39M
+22.5% YoY
|
84.30M
80.14M – 89.11M
+17.0% YoY
|
95.70M
95.69M – 95.71M
+13.5% YoY
|
| EBITDA |
-8.01M
est: -111.0K (-7,110.4%)
|
-10.37M
est: -2.87M (-261.0%)
|
-10.87M
est: -6.27M (-73.3%)
|
217.0K
est: -9.65M (+102.2%)
|
2.40M
est: -2.38M (+200.8%)
|
1.86M
est: -2.80M (+166.4%)
|
5.12M
est: -3.42M (+249.7%)
|
-4.19M
-4.26M – -4.12M
-22.5% YoY
|
-4.90M
-5.18M – -4.66M
-17.0% YoY
|
-5.56M
-5.56M – -5.56M
-13.5% YoY
|
| EBIT |
-9.63M
est: -137.8K (-6,889.0%)
|
-12.09M
est: -3.57M (-239.0%)
|
-13.27M
est: -7.79M (-70.4%)
|
-2.83M
est: -11.97M (+76.3%)
|
-722.3K
est: -5.61M (+87.1%)
|
-1.41M
est: -6.59M (+78.6%)
|
1.76M
est: -8.05M (+121.8%)
|
-9.86M
-10.04M – -9.69M
-22.5% YoY
|
-11.53M
-12.19M – -10.96M
-17.0% YoY
|
-13.09M
-13.09M – -13.09M
-13.5% YoY
|
| Net Income |
-14.27M
est: -8.78M (-62.6%)
|
-14.98M
est: -16.68M (+10.2%)
|
-14.52M
est: -16.39M (+11.4%)
|
-3.86M
est: -4.10M (+5.9%)
|
-1.82M
est: -4.13M (+55.9%)
|
-2.56M
est: -2.69M (+4.6%)
|
1.05M
est: 2.80M (-62.5%)
|
800.0K
365.0K – 1.42M
-71.4% YoY
|
8.26M
4.31M – 10.54M
+932.0% YoY
|
16.07M
15.35M – 16.89M
+94.6% YoY
|
| SGA |
10.61M
est: 245.9K (+4,216.2%)
|
12.13M
est: 6.36M (+90.7%)
|
14.58M
est: 13.89M (+5.0%)
|
16.07M
est: 21.36M (-24.8%)
|
13.93M
est: 17.39M (-19.9%)
|
16.37M
est: 20.43M (-19.9%)
|
20.12M
est: 24.94M (-19.3%)
|
30.54M
30.02M – 31.10M
+22.5% YoY
|
35.73M
33.97M – 37.77M
+17.0% YoY
|
40.56M
40.55M – 40.56M
+13.5% YoY
|
| EPS |
-0.38
est: -0.15 (-153.3%)
|
-0.34
est: -0.29 (-19.3%)
|
-0.26
est: -0.28 (+7.1%)
|
-0.07
est: -0.07 (+2.0%)
|
-0.03
est: -0.06 (+47.5%)
|
-0.04
est: -0.04 (-11.3%)
|
0.02
est: 0.05 (-65.7%)
|
0.01
0.01 – 0.02
-71.4% YoY
|
0.12
0.06 – 0.16
+825.0% YoY
|
0.24
0.23 – 0.25
+94.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 2/5 | 3/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.06M
OE per share TTM
-0.04
Owner's Yield
-8.91%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
79.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
8.5K
Shares Outstanding
67.18M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Margaret Ruth Brodie | Chief Executive Officer & Director | 474.3K | female |
| Melanie Ramsey | Chief Operating Officer | 376.6K | female |
| Calum Clayton | Director of Corporate Finance | — | male |
| Monika Mascitti | Vice President of People & Community | — | female |
| William Glenn Ibbott | Chief Financial Officer & Corporate Secretary | — | male |
| Mathieu Aubin | Vice President of Marketing & New Business | — | — |
| Chris Still | Vice President of Sales | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ROMJ.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
